Skip to main content Accessibility help
×
Hostname: page-component-84b7d79bbc-5lx2p Total loading time: 0 Render date: 2024-07-27T12:02:29.493Z Has data issue: false hasContentIssue false

S

Published online by Cambridge University Press:  05 November 2014

Henry Paw
Affiliation:
York Hospital
Rob Shulman
Affiliation:
University College London
Get access

Summary

SALBUTAMOL

Uses

Reverses bronchospasm

Administration

  1. • Nebuliser: 2.5–5 mg 6 hourly, undiluted (if prolonged delivery time desirable then dilute with sodium chloride 0.9% only) For patients with chronic bronchitis and hypercapnia, oxygen in high concentration can be dangerous, and nebulisers should be driven by air

  2. • IV: 5 mg made up to 50 ml with glucose 5% (100 μg/ml) Rate: 200–1200 μg/h (2–12 ml/h)

How not to use salbutamol

For nebuliser: do not dilute in anything other than sodium chloride 0.9% (hypotonic solution may cause bronchospasm)

Adverse effects

Tremor

Tachycardia

Paradoxical bronchospasm (stop giving if suspected)

Potentially serious hypokalaemia (potentiated by concomitant treatment with aminophylline, steroids, diuretics and hypoxia)

Cautions

Thyrotoxicosis

In patients already receiving large doses of other sympathomimetic drugs

SILDENAFIL

Sildenafil (Viagra, Revatio), epoprostenol (Flolan), bosentan (Tracleer) and sitaxentan (Thelin) are licensed for the treatment of pulmonary hypertension. Epoprostenol and sildenafil are both available for intravenous use. Sildenafil is a potent and selective inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5), the enzyme that is responsible for degradation of cGMP. Apart from the presence of this enzyme in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature.

Type
Chapter
Information
Handbook of Drugs in Intensive Care
An A-Z Guide
, pp. 209 - 218
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • S
  • Henry Paw, Rob Shulman, University College London
  • Book: Handbook of Drugs in Intensive Care
  • Online publication: 05 November 2014
  • Chapter DOI: https://doi.org/10.1017/CBO9781316182673.020
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • S
  • Henry Paw, Rob Shulman, University College London
  • Book: Handbook of Drugs in Intensive Care
  • Online publication: 05 November 2014
  • Chapter DOI: https://doi.org/10.1017/CBO9781316182673.020
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • S
  • Henry Paw, Rob Shulman, University College London
  • Book: Handbook of Drugs in Intensive Care
  • Online publication: 05 November 2014
  • Chapter DOI: https://doi.org/10.1017/CBO9781316182673.020
Available formats
×